FDA conditionally approves QYLEKI as brand name for Quoin drug
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome
June 23, 2026 8:30 AM EDTQRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDAPivotal Phase 3 Study Expected to Initiate in the Second Half of 2026, with Potential NDA Filing in 2027Positive Clinical Update from Ongoing Pediatric Compassionate Use Program Released on June 16QRX003 Remains on Track to Potentially Become the First Approved Treatment for Netherton Syndrome
ASHBURN, Va., June 23, 2026 (GLOBE NEWSWIRE) --... More
